At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 650 enrolled
Drug / intervention
ombitasvir/paritaprevir/ritonavir and dasabuvir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 3 clinical trial evaluating ombitasvir/paritaprevir/ritonavir and dasabuvir and Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir for Hepatitis C Virus (HCV). Completed, enrolled 650 participants.
Detailed Summary
This is a study to evaluate ABT 450/r/ABT-267 and ABT-333 in treatment-naïve and treatment-experienced Asian adults with subgenotype 1b chronic HCV without cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus (HCV)
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedAug 2015
Primary CompletionOct 2016
Study CompletionJun 2017
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartJul 1, 2015
Primary CompletionOct 1, 2016
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.9 years ago
Interventions
ombitasvir/paritaprevir/ritonavir and dasabuvirdrug
Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvirdrug
Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir